VEEV › analyze
VEEV · Analyze
Date: 2026-08-27 | Price at analysis: $282.13 (post-earnings, +15.2% on the day)
Baseline: Output/Stocks/Healthcare/VEEV/analyze-2026-06-04.md, 2026-06-04, price ~$167.24, conviction [8.0], verdict Strong buy / initiate at $155–168
Second-prior report read: Output/Stocks/Healthcare/VEEV/analyze-2026-04-28.md, 2026-04-28, price ~$158.49, conviction 4/5
1. What this updates
The June baseline set one explicit, dated falsification test: "Next monitoring event: FY2027 Q2 earnings (August/September 2026) — watch Vault CRM commitment count update, Falcon AI customer metrics, and whether FY2027 guidance holds." That print landed today (Aug 26, after close / Aug 27 reaction) — this is not a routine calendar refresh, it is the exact event the baseline told the next pass to go get.
Event list since 2026-06-04: - 2026-08-26/27 — Q2 FY2027 earnings. Revenue $928M (+18% YoY, beat $905M consensus by 2.5%). Non-GAAP EPS $2.35 (beat $2.22 est. by 5.9%). GAAP diluted EPS $1.66, GAAP operating income $275M (+40% YoY), non-GAAP operating income $415.9M (44.8% margin). FY2027 guidance raised: revenue to $3,682–3,687M (from $3,585–3,600M, +2.7% at midpoint), non-GAAP EPS to ~$9.21 (from an implied $8.50–9.00), non-GAAP operating income to ~$1,640M (~44% margin), non-GAAP operating cash flow to ~$1,600M. - Vault CRM: 9 → 12 of top-20 biopharma committed. Eli Lilly, Biogen and Regeneron signed in the quarter. 180+ live customers. Management (multiple outlets, consistent) characterizes competing Salesforce Life Sciences Cloud implementations as struggling — "not going smooth," "we are their plan B" — with win-back opportunities expected 2027–2028. - Falcon AI: concept → 5 named early adopters, first go-lives expected later in 2026. Investor Day scheduled 2026-11-05 specifically to detail Falcon/Aspen monetization. - Buybacks accelerated sharply. $226.9M repurchased in Q1 FY2027 alone — more than the entirety of FY2026's $170M. Diluted shares outstanding fell to 162.44M (from 163.78M at FY2026 year-end) — the first genuine net share-count decline in the file's history, not just decelerating dilution. - Stock re-rated +68.7% from the baseline's $167.24 to $282.13, including the single-day +15.2% earnings pop — "best day ever" per multiple outlets. Sell-side price targets moved in lockstep: pre-print targets clustered $175–235 (several analysts had cut PTs through June–July on Salesforce-competition fear); post-print targets moved to $270–300 (Oppenheimer $300, Baird $300, Piper Sandler $295, Barclays/Stifel/Guggenheim ~$275–276). - Insider activity: President Thomas Schwenger sold 36,000 shares ($9.0M) at $241.91–251.03 on 2026-08-13 (two weeks before earnings, already at an elevated price) plus a smaller sale in July — routine-pattern selling consistent with his multi-year 10b5-1 cadence, not a new signal.
2. Pitfall checks run before trusting any number
pitfall-single-quarter-fcf-read-as-ttm— Yahoo's quarterly cash-flow feed shows Q1 FY2027 (Apr-26) operating cash flow of $1,127M in a single quarter, which would look like an inflated "TTM" if read off one column. Reconciled instead: summed the four most recent quarters (Q3 FY26 $192.8M + Q4 FY26 $106.8M + Q1 FY27 $1,127.1M + Q2 FY27 ~$243M, backed out from the company's own disclosed $1.37B H1 FY2027 OCF) = TTM OCF ≈ $1.67B. Cross-checked: summing the four FY2026 quarters (877.2+238.4+192.8+106.8) reproduces the baseline's reported FY2026 FCF of $1,415M exactly — the quarterly figures reconcile cleanly. The Q1-heavy pattern recurs every year (Q1 FY26 was also the largest quarter at $877M) — it is Veeva's annual-invoicing collection cycle, not a data error, but it means no single quarter should ever be read as a run-rate.pitfall-vendor-forward-eps-is-the-wrong-fiscal-year— fired. Yahoo'sforwardPE(27.62x) /forwardEps($10.21) do not match the company's own FY2027 guidance of ~$9.21. CheckingepsCurrentYear/priceEpsCurrentYear($9.08 / 31.06x) shows this is the FY2027-consistent pair — Yahoo'sforwardPEfield is quoting FY2028 consensus, one year out. Any "fwd" multiple quoted directly from the vendor snapshot would have been ~10% too low (implying a cheaper stock than it is).pitfall-multiple-trim-inherits-the-broken-vendor-field— becauseforwardPEis contaminated (above) andsite.pyonly supportsfwd(forwardPE) orttm(trailingPE) as trim bases, the trim below is written on the ttm basis (trailingPE 46.25x, trailingEps $6.10 — verified: this TTM GAAP EPS reconciles to the sum of the last four quarterly GAAP EPS figures, $1.40+$1.45+$1.57+$1.66 ≈ $6.08 ≈ $6.10 reported).pitfall-yahoo-insider-purchases-counts-rsu-grants— checked. The Aug-13 Schwenger transaction is a derivative-conversion-then-sale (option exercise at $154 strike, immediately sold at $241–251), not an open-market purchase. No false "insider buying" signal generated.pitfall-fin-py-snapshot-mixes-annual-and-mrq-dates—fin.py's balance-sheet block is FY2026 year-end (Jan-26); cross-validated net cash/debt againstget_stock_info's most-recent-quarter fields (Q1 FY2027, Apr-26) rather than mixing the stale annual figure with the real-time price.pitfall-stale-entry-zone-suppresses-a-name— this is the pitfall the task exists to fix. Both the entry ($155–168) and the effective ceiling (trim $250+, strong-sell $280+) are stale; re-derived from scratch below rather than widened by drift.
3. The delta ledger
Lead rows first — nothing retracted this pass; the two most consequential rows are SUPERSEDED (price) and the resolved open item.
| # | Claim (baseline) | Type | Status | Old → New |
|---|---|---|---|---|
| 1 | Entry $155–168 / Trim $250+ / strong sell $280+ | Price | 🔄 SUPERSEDED | Stock ran through the entire old ladder (spot $282 > old strong-sell $280) — see §4. Re-derived: Entry $195–215, Trim 44x ttm (~$268) |
| 2 | Fair value $200–220 (weighted), EV/SBC-adj FCF 22.2x | Price | 🔄 SUPERSEDED | Re-derived from scratch on FY2027 company guidance: $195–271 (base ~$225–235). Current $282 sits above even the bull case |
| 3 | Open item: "Q2 FY2027 print is the next monitoring event — watch Vault CRM count, Falcon metrics, guidance" | — | ✅ RESOLVED (tested favorably) | The baseline's own falsification test. All three came back favorable: commitment count up, Falcon has named adopters, guidance raised twice over |
| 4 | Vault CRM top-20 commitment count: 9 (vs Salesforce 3–4) | State | 🔁 REFRESHED | 9/20 → 12/20 (Eli Lilly, Biogen, Regeneron added in one quarter). Corroborated across StockTitan, Investing.com, BigGo, three independent write-ups |
| 5 | Commercial CRM (~25% of rev) is the contested flank — Salesforce threat | Structural | 🔁 REFRESHED (favorably) | New evidence undercuts the threat rather than confirming it: reported Salesforce implementations "not going smooth," win-back expected 2027–28. A predicted risk that has not materialized is a force for the moat, not a reason to drop monitoring |
| 6 | Zero debt, fortress balance sheet | Structural | ✅ CARRIED | Debt $96M → $103M (still trivial, 0.2% of assets) |
| 7 | Net cash ~$6.5B (~$39.45/share) | State | 🔁 REFRESHED | $6.56B/$39.45 (FY26 YE) → ~$7.2B/~$44/share (mrq) |
| 8 | Revenue CAGR 14% / NI CAGR 23% / EPS CAGR 22% (3yr, FY23–26) | Trend | 🔁 REFRESHED | Q1+Q2 FY2027 actuals ran +18% and +18% YoY; FY2027 guide raised from 12.3% to ~15% growth. Growth is accelerating relative to the trailing 3yr trend, not decaying into it |
| 9 | GAAP op margin 21.3%→28.7% expanding; gross margin 71.7%→75.5% expanding | Trend | ✅ CARRIED | Q2 FY2027 GAAP op margin 29.6% vs Q2 FY2026's 24.8% — still expanding. Non-GAAP margin has plateaued near 44–45% (a maturity signal worth flagging, not a break) |
| 10 | Share count dilution modest (+1.2%/yr), decelerating; first buyback ($170M, FY26) | Trend | 🔁 REFRESHED (materially) | Diluted shares outstanding fell to 162.44M from 163.78M — first genuine net decline, not just deceleration. Q1 FY2027 alone repurchased $226.9M, more than all of FY2026 |
| 11 | SBC $473M / 14.8% of revenue, declining as % of revenue | Trend | ✅ CARRIED | Trend continues: TTM SBC ~13.9% of TTM revenue, still declining |
| 12 | FCF CAGR ~22% (3yr, FY23–26) | Trend | 📉 DRIFTED | TTM OCF (Q3FY26–Q2FY27) ≈ $1.67B vs FY2026's $1.415B = +18% YoY — still elite, but the FY2027 guided OCF (~$1.6B) implies ~13% full-year growth, below the 3yr historical CAGR. Breaks if guided OCF growth falls further, toward single digits, for two consecutive guides |
| 13 | FY2027 guidance: revenue $3.585–3.600B, non-GAAP op income ~$1.61B, implied EPS $8.50–9.00 | State | 🔁 REFRESHED | Raised to revenue $3.682–3.687B, non-GAAP op income ~$1.64B, non-GAAP EPS officially guided ~$9.21 (beating the baseline's own estimate) |
| 14 | Falcon AI — early stage, unproven as revenue driver, optionality only | Structural | 🔁 REFRESHED | Concept → 5 named early adopters, first go-lives expected later in 2026. Still pre-revenue in any material sense (Gassner: "would be flying off the shelf" if adopters were live — i.e., not yet) — the "unproven" core of the claim survives, but with concrete named progress |
| 15 | Vault (~70% of revenue) near-monopoly, no credible competitor | Structural | ✅ CARRIED | No counter-evidence; reinforced indirectly by the Salesforce-struggling reports above, which concern the CRM flank, not Vault's regulatory/clinical/quality core |
| 16 | ROIC ~13–14% (GAAP-denominator basis) | Trend | ✅ CARRIED | ROE 13.9% / ROA 7.3% per current snapshot — consistent |
| 17 | Evergreen rating 8/10 | Judgment | ✅ CARRIED | Life-sciences regulatory demand structurally intact; no new disruption vector surfaced |
| 18 | $1B buyback authorization (Mar-26) — capital-return signal | Structural | 🔁 REFRESHED | From authorized-but-modest ($170M/yr pace) to actively executing at 5x that pace ($226.9M in one quarter) |
| 19 | Thesis break: Vault CRM commitment count <7 | Judgment | 🔁 REFRESHED | Base moved (9→12); trigger re-anchored to <10 so it still means "losing share," not "failing to gain more" |
| 20 | Thesis break: revenue growth <10% for 2 consecutive quarters | Judgment | ✅ CARRIED | Untouched — still the right test, and further from tripping given the raise |
| 21 | Risk #1 (Salesforce erosion, could remove 8–10% of revenue) | Judgment | 📉 DRIFTED (favorably) | Severity downgraded from "primary/elevated" to "monitored" — see §4. Not retired: migration window formally runs through 2028–29 |
| 22 | Institutional ownership mixed (net reduction in Q1 2026, tax-loss-selling explanation) | State | ⏳ UNTESTED | No fresh 13F-cycle data pulled this pass — the post-print institutional reaction (buying into the beat vs. trimming into strength) is not yet observable and needs the next 13F cycle |
| 23 | Institutional buy rate / analyst consensus strongly bullish (73–88% Buy) | State | 🔁 REFRESHED | 27 analysts, recommendationKey: buy, mean target $260 (lagging the post-print re-rating — freshest individual targets are $270–300) |
| 24 | Graham's Number ($73–78) structurally inapplicable, 0% weight | Judgment | ✅ CARRIED | Recomputed at $78.44 on current TTM EPS/BVPS — same conclusion, same weight |
4. How the close calls were decided
Was Risk #1 (Salesforce) resolved or just delayed? The moat analyst's standing prior — that a structural claim holds absent a named business-model change — pointed one way; the sentiment analyst's event list (12/20 committed, named Salesforce projects struggling) pointed the same way, which is unusual: normally these two are in tension on this exact question (see the April and June baseline's own debate rounds). With both forces aligned and the count moving 9→12 in a single quarter against a rival reportedly stalling, this is adjudicated as a genuine, not merely reported, improvement — Risk #1 is downgraded but not closed, because the migration window the April baseline named (2026–2029) still has three fiscal years to run and a reversal is structurally possible if Veeva's own execution slips.
Was the FCF deceleration (claim #12) a break or a drift? Two readings compete: (a) TTM OCF growth of +18% YoY is objectively strong and beat the year-ago comp; (b) management's own forward guide (~13% OCF growth) is a deceleration from the 22% 3-year CAGR the baseline anchored on. Weighed toward (b) as the more forward-looking, primary-sourced number — but not enough to call it a break, because revenue and non-GAAP earnings guides are accelerating over the same window (12.3%→15% revenue growth), and a maturing SaaS business normally sees FCF growth converge toward revenue growth rather than staying permanently ahead of it via one-time SBC-ratio compression. Marked DRIFTED with an explicit break level (sub-10% OCF growth for two consecutive guides) rather than either CARRIED or SUPERSEDED.
Price (claims #1–2): the largest single fact in this pass. The baseline's own "strong sell $280+" line — written in June with no expectation it would be tested within three months — is where the stock trades today, almost to the dollar ($282.13 vs $280). That is not drift; it is the baseline's own ceiling being reached on schedule, which is treated as strong corroboration of both the old analysis's ceiling logic and the new analysis's independently re-derived trim (44x ttm ≈ $268, within 5% of the old $280 strong-sell line despite being built from entirely different current-year inputs). Two independent derivations three months apart landing within 5% of each other is the kind of agreement that raises confidence in the number itself, even as the verdict built on top of it changes.
5. Thesis persistence and conviction delta
Thesis persistence: of the Structural + Trend claims in the ledger (#5, #6, #8, #9, #10, #11, #12, #14, #15, #16, #18 — 11 rows), 10 survived as CARRIED or REFRESHED (all except #12, FCF CAGR, which DRIFTED). Persistence ≈ 91%.
That is the textbook re-rating setup this command's own instructions describe: the business held and the multiple moved. Every structural claim about the moat (Vault's monopoly, the Salesforce flank, Falcon's optionality, the balance sheet) either held or improved. The one drifting claim (FCF growth deceleration) is a maturity signal, not a thesis crack.
Conviction: 8.0 → 8.5. Driven by claims #4 (Vault CRM 9→12/20), #5/#21 (the predicted Salesforce attack visibly stalling rather than materializing), #10/#18 (buybacks moving from authorized to genuinely executed, shrinking the share count for the first time), and #13 (guidance raised twice running, beating the baseline's own estimate). This is a business-quality upgrade, not a valuation upgrade — see below, where the price call moves the opposite direction.
6. What is genuinely new
- Falcon AI has named customers for the first time (5 early adopters) rather than being a framing exercise on an earnings call. Still not revenue-material by management's own account.
- An Investor Day is now on the calendar (2026-11-05) specifically to detail Falcon/Aspen and the R&D-cloud product trajectory — the first hard date this file has had for that thesis variable. Set as the recheck trigger.
- Services revenue growth is accelerating (24% YoY in Q2 vs 13% a year ago) — a new, previously-unremarked data point suggesting the Vault CRM migration wave is driving real implementation/consulting demand, not just subscription bookings.
- Sell-side price targets are still catching up to the print — the Yahoo mean target ($260) sits below the freshest individual post-print targets ($270–300), meaning consensus has not yet fully repriced. Worth noting as a mechanical lag, not a signal either way.
7. Updated verdict
VEEV is a stronger business than it was in June and a worse buy at today's price than it was in June — both things are true simultaneously, and neither cancels the other.
The Salesforce threat that anchored Risk #1 in both prior reports has not materialized; if anything the evidence points the other way. Vault CRM commitment count accelerated from 9 to 12 of the top 20 in a single quarter, against a competitor reportedly struggling with its own implementations. Falcon AI moved from a slide to five named customers. The company is executing its $1B buyback authorization aggressively enough to shrink the share count outright for the first time in the file's history. Guidance has been raised in back-to-back quarters, each time beating the prior estimate rather than merely meeting it.
None of that is priced generously into $282 — it is already paid for, and then some. Re-deriving fair value from the company's own FY2027 guidance (not vendor consensus, which is contaminated by a wrong-fiscal-year forward P/E field) puts the base case at $225–235, with a genuinely generous bull case (33x EV/SBC-adjusted FCF, reflecting the improved moat evidence) at $271. Spot is above all three scenarios. The market is not wrong that the business improved — it has simply also re-rated the multiple by roughly 40% (non-GAAP current-year P/E moved from ~19x in June to ~31x today) on top of the earnings growth, and multiple expansion on top of already-strong execution is the least repeatable part of a return.
Per the First Principles table (analysis_notes.md §0): Great business + Expensive price = Wait/Watch, not Buy. The verdict moves from "initiate at $155–168" to WATCH — this is not a downgrade of the business, it is an acknowledgment that the entry window closed in the March–August rally and a new one has not yet opened.
Fair value
| Model | Basis | Result | Weight |
|---|---|---|---|
| Graham's Number | √(22.5 × $6.10 × $44.83) | $78 | 0% (structurally inapplicable — asset-light SaaS) |
| EV/SBC-adj FCF — bear (22x, FY2027E $1,110M) | company FY2027 guided OCF less estimated SBC | ~$195 | 25% |
| EV/SBC-adj FCF — base (27x) | same base | ~$225–235 | 40% |
| EV/SBC-adj FCF — bull (33x, reflecting the strengthened moat evidence) | same base | ~$271 | 25% |
| Bogle expected return (0% div + ~15% EPS growth − P/E-reversion headwind) | current-year non-GAAP P/E 31x reverting toward ~25x over 3yr | ~8%/yr forward | context only |
Fair value range: $195–271, weighted center ~$225–235. Current price $282 is ~20–45% above this range depending on scenario weighting.
Entry / Trim (re-derived from current fundamentals, not widened from the stale bands)
| Old (2026-06-04) | New (2026-08-27) | Basis | |
|---|---|---|---|
| Entry | $155–168 | $195–215 | Bear-case-to-low-base fair value; a genuine pullback zone for this quality, not a return to a cheaper multiple regime that no longer describes the business |
| Trim | $250+ (fixed $) | 44x ttm (≈$268 today) | Trailing GAAP EPS ($6.10, verified against summed quarterly EPS) — forwardPE is on FY2028 and unusable per the pitfall check in §2 |
| Strong sell | $280+ (fixed $) | (retired — the multiple-based trim now does this job continuously as EPS updates) | — |
The independently re-derived trim (~$268) lands within 5% of the baseline's untouched "strong sell $280+" — see §4. Spot ($282.13) is already above the new trim, consistent with — and a real update to, not a repeat of — the pre-print Watchlist flag that VEEV traded 14% above its old fixed-dollar trim.
Break triggers (updated)
- Vault CRM top-20 commitment count falls below 10 (from today's 12 — re-anchored per §3 row 19)
- Revenue growth decelerates below 10% for 2 consecutive quarters (unchanged — still not close)
- FY2027 guided operating-cash-flow growth falls further, toward single digits, for two consecutive guides (new — from the DRIFTED FCF claim)
- Falcon AI fails to convert its 5 early adopters to material paid adoption by the FY2028 guide cycle
Upgrade conditions (what would move this back to BUY)
- A pullback into the $195–215 entry band without a fundamental deterioration, or
- The 2026-11-05 Investor Day disclosing a credible, monetizable Falcon roadmap that the market has not yet priced (would raise the bull-case multiple further, widening the gap to spot from the top rather than the bottom)
8. What this pass did NOT test
- Institutional 13F positioning post-print (claim #22) — UNTESTED. The June baseline's "mixed institutional, net reduction" reading predates the print; the next 13F cycle (due ~mid-November) is the actual test.
- Falcon AI unit economics / pricing model — still not disclosed by the company beyond "consumption-based, likely per-document/per-case." The Nov-5 Investor Day is explicitly where this should surface; treat anything asserted about Falcon revenue potential before that date as UNTESTED.
- Full non-GAAP TTM operating income / FCF reconstruction — built the FY2027E FCF estimate from the company's own guided OCF (~$1.6B) rather than back-solving a TTM figure from incomplete quarterly non-GAAP disclosures (only Q1 and Q4 FY2026 non-GAAP op income were available piecemeal). This is a single-source, primary number (company guidance) rather than a vendor-derived TTM, which is the stronger basis, but it means the fair-value range rests on one guidance print rather than a triangulated series — worth re-checking against Q3 FY2027 actuals.
- Post-spin/segment mix update — the ~70% Vault / ~25% CRM / ~5% Data revenue split is carried unchanged from the June baseline; no fresher segment breakdown was published in the Q2 print or surfaced in this pass's sources.
Sources: .mcp/fin.py VEEV --news, Yahoo Finance MCP (get_stock_info, get_financial_statement quarterly income/cashflow, get_holder_info insider_transactions, get_recommendations upgrades_downgrades), WebSearch/WebFetch — BigGo Finance Q2 FY2027 recap, Investing.com Q2'27 slides summary, Motley Fool — Why Veeva Skyrocketed, StockTitan press-release index.